Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Milton, DT [1 ]
Kris, MG [1 ]
Azzoli, CG [1 ]
Gomez, JE [1 ]
Heelan, R [1 ]
Krug, LM [1 ]
Pao, W [1 ]
Pizzo, B [1 ]
Rizvi, NA [1 ]
Miller, VA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：646S / 646S
页数：1
相关论文
共 50 条
  • [41] Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kim, C.
    Liu, S.
    Subramaniam, D.
    Giaccone, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S479 - S479
  • [42] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥70) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Stinchcombe, T
    Socinski, M
    Choksi, J
    Bakri, K
    Taylor, M
    Tynan, M
    Mears, A
    Smith, C
    LUNG CANCER, 2005, 49 : S270 - S270
  • [43] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥ 70) with stage IIIB/IV non-small cell lung cancer (NSCLC).
    Stinchcombe, TE
    Socinski, MA
    Choksi, J
    Bakri, K
    Taylor, M
    Tynan, MT
    Mears, A
    Smith, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 685S - 685S
  • [44] Gefitinib: Phase II and III results in advanced non-small cell lung cancer
    Kelly, K
    Averbuch, S
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 93 - 99
  • [45] Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
    Asahina, Hajime
    Oizumi, Satoshi
    Inoue, Akira
    Kinoshita, Ichiro
    Ishida, Takashi
    Fujita, Yuka
    Sukoh, Noriaki
    Harada, Masao
    Maemondo, Makoto
    Saijo, Yasuo
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nukiwa, Toshihiro
    Nishimura, Masaharu
    ONCOLOGY, 2010, 79 (5-6) : 423 - 429
  • [46] A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Wozniak, A. J.
    Kalemkerian, G. P.
    Gadgeel, S. M.
    Schneider, B. J.
    Valdivieso, M.
    Venkatramanamoorthy, R.
    Hackstock, D. M.
    Chen, W.
    Heilbrun, L. K.
    Ruckdeschel, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] A PHASE II TRIAL OF PEMETREXED (P), GEMCITABINE (G), AND BEVACIZUMAB (BV) IN UNTREATED PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Wozniak, Antoinette
    Kalemkerian, Gregory
    Gadgeel, Shirish M.
    Ramnath, Nithya
    Schneider, Bryan
    Valdivieso, Manuel
    Smith, Daryn
    Hackstock, Deborah
    Chen, Wei
    Ruckdeschel, John
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1234 - S1235
  • [48] A phase II trial of biweekly administration of vinorelbine (V) and gemcitabine (G) in elderly patients (Pts) with advanced non-small cell lung cancer (NSCLC).
    Kimura, H
    Kasahara, K
    Shibata, K
    Shirasaki, H
    Iwasa, K
    Yoshimoto, A
    Kita, T
    Fuzimura, M
    Nakao, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 698S - 698S
  • [49] Phase II clinical trial of kahalalide F (KF) as a second line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Provencio, Mariano
    Izquierdo, Angel
    Vinolas, Nuria
    Paz-Ares, Luis
    Feliu, Jaime
    Constenla, Manuel
    de las Heras, Begona
    Erustes, Mercedes
    Izquierdo, Miguel A.
    Rosell, Rafael
    ANNALS OF ONCOLOGY, 2006, 17 : 225 - 225
  • [50] Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial
    Schiller, J. H.
    Larson, T.
    Ou, S. I.
    Limentani, S. A.
    Sandler, A. B.
    Vokes, E. E.
    Kim, S.
    Liau, K. F.
    Bycott, P. W.
    Olszanski, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345